<?xml version="1.0" encoding="UTF-8"?>
<p>These inherent advantages of VLPs have made them one of the most successful recombinant vaccine platforms. For example, five VLP-based vaccines for hepatitis B virus (HBV) and human papillomavirus (HPV) have been commercially licensed, and all have demonstrated excellent safety profiles and long-term protection against infection in humans [
 <xref ref-type="bibr" rid="CR000831">31</xref>]. These successes and the potential of evoking a gut mucosal immune response upon oral delivery have encouraged the preclinical and clinical development and testing of VLP-based vaccine candidates for NoV.
</p>
